Downregulation of Egr-1 Expression Level via GluN2B Underlies the Antidepressant Effects of Ketamine in a Chronic Unpredictable Stress Animal Model of Depression

Neuroscience

Volumn 372, Issue , 2018, Pages 38-45

  Zhang, Wei jie ^a   Wang, Hua hua ^b   Lv, Yi dong ^a   Liu, Cai cai ^a   Sun, Wen yao ^a   Tian, Liu jun ^a  

^a WEIFANG PEOPLE'S HOSPITAL   (China)

^b Weifang Kuiwen District Maternity and Child Care Hospital   (China)

Author keywords

antidepressant; Egr 1; GluN2B; ketamine; PSD 95

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DISKS LARGE HOMOLOG 4; EARLY GROWTH RESPONSE FACTOR 1; KETAMINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NVP AAM 077; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DLG4 PROTEIN, MOUSE; EGR1 PROTEIN, MOUSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NR2B NMDA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC UNPREDICTABLE STRESS; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; FORCED SWIM TEST; HIPPOCAMPAL SLICE; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DENDRITIC SPINE; DISEASE MODEL; DRUG EFFECT; HIPPOCAMPUS; MENTAL STRESS; METABOLISM; PATHOLOGY; TISSUE CULTURE TECHNIQUE; UNCERTAINTY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DENDRITIC SPINES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DISKS LARGE HOMOLOG 4 PROTEIN; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; HIPPOCAMPUS; KETAMINE; MALE; MICE, INBRED C57BL; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; TISSUE CULTURE TECHNIQUES; UNCERTAINTY;

EID: 85040669981     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2017.12.045     Document Type: Article

References (35)

1. Bao, J., Lin, H., Ouyang, Y., Lei, D., Osman, A., Kim, T.W., Mei, L., Dai, P., Ohlemiller, K.K., Ambron, R.T., Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. Nat Neurosci 7 (2004), 1250–1258.
2. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H., Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
3. Chen, C., Hu, Q., Yan, J., Yang, X., Shi, X., Lei, J., Chen, L., Huang, H., Han, J., Zhang, J.H., Zhou, C., Early inhibition of HIF-1alpha with small interfering RNA reduces ischemic-reperfused brain injury in rats. Neurobiol Dis 33 (2009), 509–517.
4. Chen, X., Vinade, L., Leapman, R.D., Petersen, J.D., Nakagawa, T., Phillips, T.M., Sheng, M., Reese, T.S., Mass of the postsynaptic density and enumeration of three key molecules. Proc Natl Acad Sci U S A 102 (2005), 11551–11556.
5. Cole, A.J., Saffen, D.W., Baraban, J.M., Worley, P.F., Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation. Nature 340 (1989), 474–476.
6. Deutschenbaur, L., Beck, J., Kiyhankhadiv, A., Muhlhauser, M., Borgwardt, S., Walter, M., Hasler, G., Sollberger, D., Lang, U.E., Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry 64 (2016), 325–333.
7. Duman, R.S., Voleti, B., Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35 (2012), 47–56.
8. Ehrlich, I., Malinow, R., Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci 24 (2004), 916–927.
9. Elias, G.M., Funke, L., Stein, V., Grant, S.G., Bredt, D.S., Nicoll, R.A., Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins. Neuron 52 (2006), 307–320.
10. Englisch, S., Inta, D., Eer, A., Zink, M., Bupropion for depression in schizophrenia. Clin Neuropharmacol 33 (2010), 257–259.
11. Farley, S., Apazoglou, K., Witkin, J.M., Giros, B., Tzavara, E.T., Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 13 (2010), 1207–1218.
12. Hetzler, B.E., Wautlet, B.S., Ketamine-induced locomotion in rats in an open-field. Pharmacol Biochem Behav 22 (1985), 653–655.
13. Holmseth, S., Scott, H.A., Real, K., Lehre, K.P., Leergaard, T.B., Bjaalie, J.G., Danbolt, N.C., The concentrations and distributions of three C-terminal variants of the GLT1 (EAAT2; slc1a2) glutamate transporter protein in rat brain tissue suggest differential regulation. Neuroscience 162 (2009), 1055–1071.
14. Kallarackal, A.J., Kvarta, M.D., Cammarata, E., Jaberi, L., Cai, X., Bailey, A.M., Thompson, S.M., Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J Neurosci 33 (2013), 15669–15674.
15. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
16. Kocsis, B., Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 71 (2012), 987–995.
17. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., MTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
18. Liu, W.X., Wang, J., Xie, Z.M., Xu, N., Zhang, G.F., Jia, M., Zhou, Z.Q., Hashimoto, K., Yang, J.J., Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. Psychopharmacology 233 (2016), 405–415.
19. Luscher, C., Nicoll, R.A., Malenka, R.C., Muller, D., Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat Neurosci 3 (2000), 545–550.
20. Ma, X.C., Dang, Y.H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.G., Hashimoto, K., Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One, 8, 2013, e56053.
21. Maeng, S., Zarate, C.A. Jr., Du, J., Schloesser, R.J., McCammon, J., Chen, G., Manji, H.K., Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63 (2008), 349–352.
22. Mathew, S.J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., Murrough, J.W., Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26 (2012), 189–204.
23. Messer, M., Haller, I.V., Larson, P., Pattison-Crisostomo, J., Gessert, C.E., The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 22 (2010), 442–444.
24. Miller, O.H., Yang, L., Wang, C.C., Hargroder, E.A., Zhang, Y., Delpire, E., Hall, B.J., GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife, 3, 2014, e03581.
25. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., Seeburg, P.H., Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256 (1992), 1217–1221.
26. Muller, M.B., Lucassen, P.J., Yassouridis, A., Hoogendijk, W.J., Holsboer, F., Swaab, D.F., Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 14 (2001), 1603–1612.
27. Paul, R.K., Singh, N.S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C.E., O'Loughlin, K., Torjman, M.C., Bernier, M., Wainer, I.W., (R, S)-Ketamine metabolites (R, S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology 121 (2014), 149–159.
28. Preskorn, S.H., Baker, B., Kolluri, S., Menniti, F.S., Krams, M., Landen, J.W., An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28 (2008), 631–637.
29. Qin, X., Jiang, Y., Tse, Y.C., Wang, Y., Wong, T.P., Paudel, H.K., Early growth response 1 (Egr-1) regulates N-methyl-d-aspartate receptor (NMDAR)-dependent transcription of PSD-95 and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) trafficking in hippocampal primary neurons. J Biol Chem 290 (2015), 29603–29616.
30. Shirayama, Y., Yang, C., Zhang, J.C., Ren, Q., Yao, W., Hashimoto, K., Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25 (2015), 2449–2458.
31. Slattery, D.A., Morrow, J.A., Hudson, A.L., Hill, D.R., Nutt, D.J., Henry, B., Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology 30 (2005), 1278–1287.
32. Thiel, G., Mayer, S.I., Muller, I., Stefano, L., Rossler, O.G., Egr-1-A Ca(2+)-regulated transcription factor. Cell Calcium 47 (2010), 397–403.
33. Usun, Y., Eybrard, S., Meyer, F., Louilot, A., Ketamine increases striatal dopamine release and hyperlocomotion in adult rats after postnatal functional blockade of the prefrontal cortex. Behav Brain Res 256 (2013), 229–237.
34. Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Hashimoto, K., Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol, 18, 2015, pyu121.
35. Zhang, H., Etherington, L.A., Hafner, A.S., Belelli, D., Coussen, F., Delagrange, P., Chaouloff, F., Spedding, M., Lambert, J.J., Choquet, D., Groc, L., Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry 18 (2013), 471–484.